Nanotechnology Approaches for Prevention and Treatment of Chemotherapy‐Induced Neurotoxicity, Neuropathy, and Cardiomyopathy in Breast and Ovarian Cancer Survivors

• Published in: Small (Weinheim an der Bergstrasse, Germany) Germany), 2024-10, Vol.20 (41), p.e2300744-n/a
• Main Authors: Nevins, Sarah, McLoughlin, Callan D., Oliveros, Alfredo, Stein, Joshua B., Rashid, Mohammad Abdur, Hou, Yannan, Jang, Mi‐Hyeon, Lee, Ki‐Bum
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Breast cancer; Breast Neoplasms - drug therapy; Cancer; Cancer Survivors; Cardiomyopathies - chemically induced; Cardiomyopathies - prevention & control; Cardiomyopathy; Chemotherapy; Drug delivery systems; Effectiveness; Female; Humans; Nanomaterials; Nanoparticles; Nanoparticles - chemistry; Nanotechnology; Nanotechnology - methods; nanotechnology and nanomedicine; neuropathy; Neurotoxicity; Neurotoxicity Syndromes - etiology; Neurotoxicity Syndromes - prevention & control; ovarian and breast cancer; Ovarian cancer; Ovarian Neoplasms - drug therapy; Pharmacology; Side effects; Survival
• ISSN: 1613-6810; 1613-6829; 1613-6829
• DOI: 10.1002/smll.202300744

Nanotechnology has emerged as a promising approach for the targeted delivery of therapeutic agents while improving their efficacy and safety. As a result, nanomaterial development for the selective targeting of cancers, with the possibility of treating off‐target, detrimental sequelae caused by chemotherapy, is an important area of research. Breast and ovarian cancer are among the most common cancer types in women, and chemotherapy is an essential treatment modality for these diseases. However, chemotherapy‐induced neurotoxicity, neuropathy, and cardiomyopathy are common side effects that can affect breast and ovarian cancer survivors quality of life. Therefore, there is an urgent need to develop effective prevention and treatment strategies for these adverse effects. Nanoparticles (NPs) have extreme potential for enhancing therapeutic efficacy but require continued research to elucidate beneficial interventions for women cancer survivors. In short, nanotechnology‐based approaches have emerged as promising strategies for preventing and treating chemotherapy‐induced neurotoxicity, neuropathy, and cardiomyopathy. NP‐based drug delivery systems and therapeutics have shown potential for reducing the side effects of chemotherapeutics while improving drug efficacy. In this article, the latest nanotechnology approaches and their potential for the prevention and treatment of chemotherapy‐induced neurotoxicity, neuropathy, and cardiomyopathy in breast and ovarian cancer survivors are discussed. Advancements in nanomedicine have led to great potential for improving the fundamental flaws in chemotherapeutics for breast and ovarian cancer treatment. Many women who survive these impactful diseases have reduced quality of life due to off‐target effects from chemotherapy. Nanomaterials have further been applied to advance potential treatments for these debilitating effects induced by chemotherapy including cardiomyopathy, neuropathy, and neurotoxicity.